-
1
المؤلفون: Ramaswami, R, Pria, AD, Roe, J, Nelson, M, Gazzard, B, Bower, M, Chia, G
المصدر: 22nd Annual Conference of the British HIV Association (BHIVA)
مصطلحات موضوعية: Science & Technology, Infectious Diseases, Virology, 1103 Clinical Sciences, Life Sciences & Biomedicine
URL الوصول: https://explore.openaire.eu/search/publication?articleId=od______1032::d18d3b7d8d4e3efe2c864eebd217219f
http://hdl.handle.net/10044/1/51106 -
2
المؤلفون: Arvind, DA, Wright, OW, Pria, AD, Holmes, P, Singh, G, Forni, J, Nelson, M, Bower, M
المصدر: 22nd Annual Conference of the British HIV Association (BHIVA)
مصطلحات موضوعية: Science & Technology, Infectious Diseases, Virology, 1103 Clinical Sciences, Life Sciences & Biomedicine
URL الوصول: https://explore.openaire.eu/search/publication?articleId=od______1032::89641ee5d45a57efb60eb7b4a9cb2f36
http://hdl.handle.net/10044/1/51103 -
3
المؤلفون: Haq, I-U, Pria, AD, Papanastasopoulos, P, Stegmann, K, Bradshaw, D, Nelson, M, Bower, M
مصطلحات موضوعية: Male, multicentric Castleman disease, INTERLEUKIN-6, SAMPLES, viruses, HIV Infections, KSHV, PERIPHERAL-BLOOD, THERAPY, Giant Lymph Node Hyperplasia, non-AIDS-defining malignancy, Virology, Biomarkers, Tumor, Humans, Sarcoma, Kaposi, HHV-8, Science & Technology, non-Hodgkin lymphoma, virus diseases, HIV, Kaposi sarcoma, 1103 Clinical Sciences, DNA, REMISSION, biochemical phenomena, metabolism, and nutrition, QUANTIFICATION, Viral Load, Prognosis, Survival Analysis, CD4 Lymphocyte Count, AIDS, Infectious Diseases, DNA, Viral, Herpesvirus 8, Human, Female, Life Sciences & Biomedicine, MULTICENTRIC CASTLEMAN-DISEASE, HUMAN-HERPESVIRUS-8
URL الوصول: https://explore.openaire.eu/search/publication?articleId=od______1032::7bdf2292e0f699eacc7f71b9dc281bed
http://hdl.handle.net/10044/1/50718 -
4دورية أكاديمية
المؤلفون: Mostaghim A; Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, USA; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, USA., Minkove S; Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, USA., Aguilar-Company J; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; Infectious Diseases, Vall d'Hebron University Hospital, Barcelona, Spain., Ruiz-Camps I; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; Infectious Diseases, Vall d'Hebron University Hospital, Barcelona, Spain., Eremiev-Eremiev S; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; Infectious Diseases, Vall d'Hebron University Hospital, Barcelona, Spain., Dettorre GM; Department of Internal Medicine, Washington University School of Medicine, St. Louis, USA., Fox L; Department of Hematology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain., Tondini C; Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy., Brunet J; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain., Carmona-García M; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain., Lambertini M; Medical Oncology Department, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy., Bower M; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK., Newsom-Davis T; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK., Sharkey R; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK., Pria AD; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK., Rossi M; Oncology Unit, Azienda Ospedaliera 'SS Antonio e Biagio e Cesare Arrigo', Alessandria, Italy., Plaja A; Medical Oncology Department, B-ARGO Group, IGTP, Catalan Institute of Oncology-Badalona, Spain., Salazar R; Department of Medical Oncology, ICO L'Hospitalet, Oncobell Program (IDIBELL), CIBERONC, Hospitalet de Llobregat, Barcelona, Spain., Sureda A; Haematology Department, ICO Hospitalet, Hospitalet de Llobregat, IDIBELL, Universitat de Barcelona, Barcelona, Spain., Prat A; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain., Michalarea V; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK., Van Hemelrijck M; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK., Sita-Lumsden A; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK., Bertuzzi A; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy., Rimassa L; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, Milan, Italy., Rossi S; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy., Rizzo G; Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Pedrazzoli P; Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy., Lee AJ; Cancer Division, University College London Hospital, London, UK., Murphy C; Cancer Division, University College London Hospital, London, UK., Belessiotis K; Cancer Division, University College London Hospital, London, UK., Diamantis N; Medical Oncology, Barts Health NHS Trust, London, UK., Mukherjee U; Medical Oncology, Barts Health NHS Trust, London, UK., Pommeret F; Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France., Stoclin A; Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France., Martinez-Vila C; Fundació Althaia Manresa, Manresa, Spain., Bruna R; Division of Haematology, Department of Translational Medicine, University of Piemonte Orientale and Ospedale Maggiore della Carità Hospital, Novara, Italy., Gaidano G; Division of Haematology, Department of Translational Medicine, University of Piemonte Orientale and Ospedale Maggiore della Carità Hospital, Novara, Italy., D'Avanzo F; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy., Gennari A; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy., Athale J; Critical Care Medicine, Mayo Clinic Arizona, Phoenix, USA., Eichacker P; Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, USA., Pinato DJ; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy; Department of Surgery and Cancer, Imperial College of London, Hammersmith Hospital Campus, London, UK., Torabi-Parizi P; Critical Care Medicine Department, Clinical Center and National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892., Cortellini A; Department of Surgery and Cancer, Imperial College of London, Hammersmith Hospital Campus, London, UK; Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128, Roma, Italy. Electronic address: a.cortellini@imperial.ac.uk.
مؤلفون مشاركون: OnCovid study group
المصدر: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2024 Feb; Vol. 139, pp. 13-20. Date of Electronic Publication: 2023 Nov 27.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: Elsevier Country of Publication: Canada NLM ID: 9610933 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3511 (Electronic) Linking ISSN: 12019712 NLM ISO Abbreviation: Int J Infect Dis Subsets: MEDLINE
مواضيع طبية MeSH: COVID-19*/complications , Neoplasms*/complications , Neoplasms*/drug therapy, Humans ; Male ; COVID-19 Testing ; Immune Checkpoint Inhibitors/therapeutic use ; Hospitalization ; Registries ; Retrospective Studies
-
5دورية أكاديمية
المؤلفون: Pierson SK; Center for Cytokine Storm Treatment & Laboratory, Department of Medicine, University of Pennsylvania, Philadelphia, PA.; Castleman Disease Collaborative Network, Philadelphia, PA., Shenoy S; Medidata Solutions, New York, NY., Oromendia AB; Medidata Solutions, New York, NY., Gorzewski AM; Center for Cytokine Storm Treatment & Laboratory, Department of Medicine, University of Pennsylvania, Philadelphia, PA.; Castleman Disease Collaborative Network, Philadelphia, PA., Langan Pai RA; Center for Cytokine Storm Treatment & Laboratory, Department of Medicine, University of Pennsylvania, Philadelphia, PA., Nabel CS; Castleman Disease Collaborative Network, Philadelphia, PA., Ruth JR; Castleman Disease Collaborative Network, Philadelphia, PA., Parente SAT; Center for Cytokine Storm Treatment & Laboratory, Department of Medicine, University of Pennsylvania, Philadelphia, PA.; Castleman Disease Collaborative Network, Philadelphia, PA., Arenas DJ; Center for Cytokine Storm Treatment & Laboratory, Department of Medicine, University of Pennsylvania, Philadelphia, PA.; Castleman Disease Collaborative Network, Philadelphia, PA., Guilfoyle M; Janssen Pharmaceuticals, Raritan, NJ., Reddy M; Janssen Pharmaceuticals, Raritan, NJ., Weinblatt M; Department of Medicine, Brigham and Women's Hospital, Boston, MA., Shadick N; Department of Medicine, Brigham and Women's Hospital, Boston, MA., Bower M; Department of Medicine, Chelsea & Westminster Hospital, London, United Kingdom., Pria AD; Department of Medicine, Chelsea & Westminster Hospital, London, United Kingdom., Masaki Y; Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan., Katz L; Medidata Solutions, New York, NY., Mezey J; Department of Genetic Medicine, Weill Cornell Medicine, New York, NY., Beineke P; Medidata Solutions, New York, NY., Lee D; Medidata Solutions, New York, NY., Tendler C; Janssen Pharmaceuticals, Raritan, NJ., Kambayashi T; Center for Cytokine Storm Treatment & Laboratory, Department of Medicine, University of Pennsylvania, Philadelphia, PA., Fosså A; Department of Oncology, Oslo University Hospital, Oslo, Norway.; K.G. Jebsen Centre for B-cell Malignancies, University of Oslo, Oslo, Norway; and., van Rhee F; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR., Fajgenbaum DC; Center for Cytokine Storm Treatment & Laboratory, Department of Medicine, University of Pennsylvania, Philadelphia, PA.; Castleman Disease Collaborative Network, Philadelphia, PA.
المصدر: Blood advances [Blood Adv] 2021 Sep 14; Vol. 5 (17), pp. 3445-3456.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
مواضيع طبية MeSH: Castleman Disease*/drug therapy , Herpesvirus 8, Human*, Humans ; Interleukin-6 ; Proteomics ; Signal Transduction ; United States
-
6تقرير
المؤلفون: Prendecki M; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London W12 0NN, UK; Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK. Electronic address: m.prendecki@imperial.ac.uk., Clarke C; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London W12 0NN, UK; Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK., Brown J; Department of Infectious Diseases, Imperial College London, London W12 0NN, UK., Cox A; Department of Infection and Immunity North West London Pathology NHS Trust, London, UK., Gleeson S; Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK., Guckian M; Department of Infection and Immunity North West London Pathology NHS Trust, London, UK., Randell P; Department of Infection and Immunity North West London Pathology NHS Trust, London, UK., Pria AD; Department of Infectious Diseases, Imperial College London, London W12 0NN, UK; Department of HIV and Genitourinary Medicine, Chelsea and Westminster Hospital, London, UK., Lightstone L; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London W12 0NN, UK; Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK., Xu XN; Department of Infectious Diseases, Imperial College London, London W12 0NN, UK., Barclay W; Department of Infectious Diseases, Imperial College London, London W12 0NN, UK., McAdoo SP; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London W12 0NN, UK; Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK., Kelleher P; Department of Infectious Diseases, Imperial College London, London W12 0NN, UK; Department of Infection and Immunity North West London Pathology NHS Trust, London, UK; Department of HIV and Genitourinary Medicine, Chelsea and Westminster Hospital, London, UK., Willicombe M; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London W12 0NN, UK; Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK.
المصدر: Lancet (London, England) [Lancet] 2021 Mar 27; Vol. 397 (10280), pp. 1178-1181. Date of Electronic Publication: 2021 Feb 25.
نوع المنشور: Letter; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
مواضيع طبية MeSH: COVID-19/*immunology , COVID-19 Vaccines/*administration & dosage , Immunity, Humoral/*drug effects , SARS-CoV-2/*immunology , Spike Glycoprotein, Coronavirus/*immunology , T-Lymphocytes/*drug effects, Adult ; Aged ; BNT162 Vaccine ; Enzyme-Linked Immunospot Assay ; Humans ; Middle Aged
-
7دورية أكاديمية
المؤلفون: Black JR; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W120HS, UK.; Department of Oncology, Chelsea & Westminster Hospital, 369 Fulham Road, Chelsea, London SW10 9NH, UK., Goldin RD; Department of Cellular Pathology, Imperial College London, Clarence Wing, St Mary's Hospital Campus, Praed St, Paddington, London W2 1NY, UK., Foxton M; Department of Gastroenterology & Hepatology, Chelsea & Westminster Hospital, 369 Fulham Road, Chelsea, London SW10 9NH, UK., Marafioti T; Department of Histopathology, University College London, 4th Floor Rockefeller Building, 21 University Street, London WC1E 6DE, UK., Akarca AU; Department of Histopathology, University College London, 4th Floor Rockefeller Building, 21 University Street, London WC1E 6DE, UK., Pria AD; Department of Oncology, Chelsea & Westminster Hospital, 369 Fulham Road, Chelsea, London SW10 9NH, UK., Brock C; Department of Oncology, Chelsea & Westminster Hospital, 369 Fulham Road, Chelsea, London SW10 9NH, UK., Bower M; Department of Oncology, Chelsea & Westminster Hospital, 369 Fulham Road, Chelsea, London SW10 9NH, UK., Pinato DJ; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London W120HS, UK.; Department of Oncology, Chelsea & Westminster Hospital, 369 Fulham Road, Chelsea, London SW10 9NH, UK.
المصدر: Immunotherapy [Immunotherapy] 2019 May; Vol. 11 (7), pp. 585-590.
نوع المنشور: Case Reports; Journal Article
بيانات الدورية: Publisher: Future Medicine Country of Publication: England NLM ID: 101485158 Publication Model: Print Cited Medium: Internet ISSN: 1750-7448 (Electronic) Linking ISSN: 1750743X NLM ISO Abbreviation: Immunotherapy Subsets: MEDLINE
مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Drug-Related Side Effects and Adverse Reactions/*diagnosis , Granuloma/*diagnosis , Hepatitis/*diagnosis , Immunotherapy/*methods , Ipilimumab/*therapeutic use , Liver/*metabolism , Melanoma/*drug therapy , Neoplasms, Unknown Primary/*drug therapy , Nivolumab/*therapeutic use, Adrenal Cortex Hormones/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; B7-H1 Antigen/genetics ; B7-H1 Antigen/metabolism ; Biopsy ; CTLA-4 Antigen/antagonists & inhibitors ; Drug Resistance ; Granuloma/etiology ; Hepatitis/etiology ; Humans ; Immunotherapy/adverse effects ; Ipilimumab/adverse effects ; Liver/pathology ; Macrophages/immunology ; Male ; Middle Aged ; Nivolumab/adverse effects ; Programmed Cell Death 1 Receptor/antagonists & inhibitors
-
8دورية أكاديمية
المؤلفون: Pria AD; Department of Oncology, The Chelsea and Westminster Hospital, London, United Kingdom., Pinato D; Department of Oncology, The Chelsea and Westminster Hospital, London, United Kingdom., Roe J; Department of HIV Medicine, The Chelsea and Westminster Hospital, London, United Kingdom; and., Naresh K; Department of Pathology, Imperial College School of Medicine, London, United Kingdom., Nelson M; Department of HIV Medicine, The Chelsea and Westminster Hospital, London, United Kingdom; and., Bower M; Department of Oncology, The Chelsea and Westminster Hospital, London, United Kingdom.
المصدر: Blood [Blood] 2017 Apr 13; Vol. 129 (15), pp. 2143-2147. Date of Electronic Publication: 2017 Jan 31.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
مواضيع طبية MeSH: Castleman Disease*/complications , Castleman Disease*/diagnosis , Castleman Disease*/drug therapy , Castleman Disease*/mortality , HIV Seropositivity*/complications , HIV Seropositivity*/diagnosis , HIV Seropositivity*/drug therapy , HIV Seropositivity*/mortality , Herpesviridae Infections*/complications , Herpesviridae Infections*/diagnosis , Herpesviridae Infections*/drug therapy , Herpesviridae Infections*/mortality , Herpesvirus 8, Human*, Rituximab/*administration & dosage, Adult ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Male ; Recurrence ; Retrospective Studies ; Survival Rate
SCR Disease Name: Multi-centric Castleman's Disease
-
9دورية أكاديمية
المؤلفون: Ramaswami R; National Centre for HIV Malignancies, Chelsea & Westminster Hospital, London, UK., Pria AD; National Centre for HIV Malignancies, Chelsea & Westminster Hospital, London, UK., Parker K; National Centre for HIV Malignancies, Chelsea & Westminster Hospital, London, UK., McCann S; National Centre for HIV Malignancies, Chelsea & Westminster Hospital, London, UK., Kanfer EJ; Department of Haematology, Hammersmith Hospital, London, UK., Nelson M; National Centre for HIV Malignancies, Chelsea & Westminster Hospital, London, UK., Bower M; National Centre for HIV Malignancies, Chelsea & Westminster Hospital, London, UK.
المصدر: Bone marrow transplantation [Bone Marrow Transplant] 2016 Dec; Vol. 51 (12), pp. 1609-1611. Date of Electronic Publication: 2016 Sep 05.
نوع المنشور: Journal Article
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8702459 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5365 (Electronic) Linking ISSN: 02683369 NLM ISO Abbreviation: Bone Marrow Transplant Subsets: MEDLINE
مواضيع طبية MeSH: Stem Cell Transplantation*, HIV Infections/*therapy , Lymphoma/*therapy, Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Female ; HIV Infections/complications ; Hematopoietic Stem Cell Transplantation ; Humans ; Incidence ; Lymphoma/complications ; Male ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Prospective Studies ; Recurrence ; Transplantation, Autologous ; Treatment Outcome ; Young Adult
-
10دورية أكاديمية
المؤلفون: Coutinho R; aCentre for Haemato-Oncology, Barts Cancer Institute, QMUL bMedical Oncology, Chelsea and Westminster Hospital cHaematological Medicine, King's College Hospital dDepartment of Haematology, Royal Free Hospital eHaematology, Guys and St Thomas Hospital fDepartment of Oncology, Brighton and Sussex University Hospital, Brighton gDepartment of Sexual Health, King's College Hospital hHIV medicine, Royal Free Hospital iInfection and Immunity, Barts Health NHS Trust jHaemato-Oncology Department, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK., Pria AD, Gandhi S, Bailey K, Fields P, Cwynarski K, Wilson A, Papanastasopoulos P, Tenant-Flowers M, Webb A, Burns F, Marcus RE, Orkin C, Montoto S, Bower M
المصدر: AIDS (London, England) [AIDS] 2014 Mar 13; Vol. 28 (5), pp. 689-97.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 8710219 Publication Model: Print Cited Medium: Internet ISSN: 1473-5571 (Electronic) Linking ISSN: 02699370 NLM ISO Abbreviation: AIDS Subsets: MEDLINE
مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , HIV Infections/*complications , Lymphoma, Large B-Cell, Diffuse/*drug therapy, Adolescent ; Adult ; Aged ; Antibodies, Monoclonal, Murine-Derived/therapeutic use ; Cyclophosphamide/therapeutic use ; Doxorubicin/therapeutic use ; Female ; Humans ; Lymphoma, Large B-Cell, Diffuse/mortality ; Lymphoma, Large B-Cell, Diffuse/pathology ; Male ; Middle Aged ; Prednisone/therapeutic use ; Rituximab ; Survival Analysis ; Treatment Outcome ; Vincristine/therapeutic use ; Young Adult